Biohaven (BHVN) Aktievy

BHVN fundamental analys
Snöflinga Score
Värdering	0/6
Framtida tillväxt	2/6
Tidigare resultat	0/6
Finansiell hälsa	3/6
Utdelningar	0/6

Belöningar

Intäkterna förväntas växa med 67.15% per år

Riskanalys

Ger mindre än 1 miljon USD i intäkter ( $0 )

Har mindre än 1 år av cash runway

Aktieägarna har varit kraftigt utspädda under det senaste året

För närvarande olönsamt och förväntas inte bli lönsamt under de kommande 3 åren

+ 1 större risk

BHVN Community Fair Values

Create Narrative

See what 14 others think this stock is worth. Follow their fair value or set your own to get alerts.

NEW499,625 members

Join community and earn perks

Gain real feedbackFrom our editorial team, personally. Not silence.

Grow your followingReal investors. The kind who actually invest, not scroll past.

Unlock free accessFree premium subscription for consistent and quality authors.

Learn more Create Narrative

499,625 investors already sharing narratives

View all narratives

Biohaven Ltd. Konkurrenter

Prishistorik och prestanda

Sammanfattning av aktiekursernas upp- och nedgångar samt förändringar för Biohaven
Historiska aktiekurser
Aktuell aktiekurs	US$16.05
52 veckors högsta	US$18.57
52 veckors lägsta	US$7.48
Beta	3.14
1 månads förändring	48.61%
3 månaders förändring	73.33%
1 års förändring	16.39%
3 års förändring	-30.88%
5 års förändring	n/a
Förändring sedan börsintroduktionen	119.86%

Senaste nyheter och uppdateringar

Analysartikel • Jun 21

Biohaven (BHVN) Stock Looks Rich After Pivotal Trial Plans Lift Shares

Biohaven (BHVN) drew investor attention after its stock rose 12.66% as the company outlined plans to start pivotal clinical studies for several cancer and autoimmune candidates in its pipeline. See our latest analysis for Biohaven. Looking beyond the latest jump, Biohaven’s share price return has been strong over shorter periods, with a 20.3% 7 day and 43.6% 30 day move. However, the 1 year total shareholder return declined 6.2%, which suggests recent momentum is rebuilding after a weaker...

Seeking Alpha • Jun 18

Biohaven: Upgrading To Buy On Protein Degraders Pivotal Study Initiations

Summary Biohaven (BHVN) is upgraded from "Hold" to "Buy," driven by FDA regulatory shifts and strong biomarker data for its protein degrader pipeline. The company is set to initiate pivotal studies for BHV-1300 in Graves' Disease and BHV-1400 in IgA Nephropathy in mid-2026, targeting large unmet markets. Phase 1b data show over 80% reduction in pathogenic TSHR-IgG1 for BHV-1300 and over 60% Gd-IgA1 reduction for BHV-1400, with safety advantages over competitors. With $351.8M cash as of March 2026 and additional equity capacity, the company is funded for at least one year, supporting multiple upcoming catalysts. Read the full article on Seeking Alpha

Recent updates

Analysartikel • Jun 21

Biohaven (BHVN) Stock Looks Rich After Pivotal Trial Plans Lift Shares

Seeking Alpha • Jun 18

Biohaven: Upgrading To Buy On Protein Degraders Pivotal Study Initiations

Analysartikel • May 02

An Intrinsic Calculation For Biohaven Ltd. (NYSE:BHVN) Suggests It's 47% Undervalued

Key Insights Biohaven's estimated fair value is US$42.26 based on 2 Stage Free Cash Flow to Equity Current share price...

Seeking Alpha • Feb 28

Biohaven's Exciting Year Of Catalysts

Summary Following Pfizer's acquisition, Biohaven's valuation surged from $300M at $7/share to over $4B at $42/share under Vlad Coric's leadership. Despite the significant valuation increase, substantial upside remains due to Biohaven's promising later-stage clinical assets with key catalysts expected in 2025. The investment thesis hinges on the potential success of these clinical assets, which could drive further valuation growth. The current valuation rise is justified by the strategic leadership and promising pipeline, suggesting continued growth potential. Read the full article on Seeking Alpha

Seeking Alpha • Feb 11

Biohaven: Highly Priced Biotech With Broad Pipeline But No Revenues

Summary Biohaven's pipeline is broad with multiple late stage molecules. Analysis based on Biohaven's 01/2025 J.P. Morgan Healthcare Conference Highlights and Presentation, Q3 2024 Earnings Release, and 10-Q. Biohaven's lead product's NDA is under review by the FDA. Article concludes with a "Hold" rating based on its hefty market cap and uncertain prospects. Read the full article on Seeking Alpha

Seeking Alpha • Nov 29

Biohaven's Revenue Path: SCA And Obesity Therapies

Summary Biohaven’s pipeline progression includes Troriluzole for spinocerebellar ataxia [SCA], which has shown a 50-70% reduction in disease progression over three years. BHV-2100, a non-opioid migraine treatment, targets unmet needs in a market affecting 40 million U.S. patients and 1 billion globally. Taldefgrobep Alfa, under investigation for SMA and obesity, demonstrated subgroup-specific motor function improvements and favorable safety in Phase 3 trials. Despite a $250 million equity raise, BHVN's cash burn of $141.9 million per quarter poses financial sustainability risks, making commercialization critical. Therefore, BHVN's positive clinical progress, high cash burn, and frequent equity raises make it a speculative buy. Read the full article on Seeking Alpha

Seeking Alpha • Oct 11

Biohaven: A Complicated Tale

Summary Biohaven's stock has surged despite past setbacks, driven by promising data from its troriluzole trials for spinocerebellar ataxia and ongoing OCD studies. The company is advancing a diverse pipeline, including myostatin inhibitor taldefgrobep alfa for SMA and obesity, and Kv7 ion channel activator BHV-7000 for epilepsy. Biohaven's strategic capital raises, and positive clinical data have rallied its stock, but future dilution risks remain if trials disappoint. An updated analysis of Biohaven follows in the paragraphs below. Read the full article on Seeking Alpha

Seeking Alpha • Sep 23

Biohaven: Positive SCA Treatment Data Leads To Q4 2024 NDA Submission Catalyst

Summary Biohaven Ltd. reported positive results from a pivotal study using troriluzole for the treatment of patients with spinocerebellar ataxia; the Drug achieved 50% to 70% of slowing of disease progression over 3 years. With positive data on hand from the phase 3 study using troriluzole for patients with spinocerebellar ataxia, an NDA submission is planned for Q4 of 2024. Troriluzole is also being explored for patients with obsessive compulsive disorder in two phase 3 studies; Data from these studies are expected before the end of 2024 and the 1st half of 2025. Topline data from the phase 3 study using Taldefgrobep Alfa for SMA is expected 2nd half of 2024; the Drug is also expected to be initiated in a phase 2 study for obesity as well. Read the full article on Seeking Alpha

Seeking Alpha • Jul 26

Biohaven: Taldefgrobep Alfa Might Have A Place Beyond SMA Treatment

Summary Results from phase 3 RESILIENT study, using taldefgrobep alfa for the treatment of patients with spinal muscular atrophy, expected in the 2nd half of 2024. The global spinal muscular atrophy treatment market is projected to reach $8.4 billion by 2032. Preclinical model testing showed that myostatin inhibitor taldefgrobep alfa + GLP-1 inhibitor was able to show greater reductions in body weight and fat loss, compared to that of GLP-1 alone. It is expected that the global obesity treatment market size is expected to be worth $38 billion by 2032. Read the full article on Seeking Alpha

Seeking Alpha • May 18

Biohaven: Promising Pipeline With Troriluzole, Taldefgrobep Alfa, And BHV-7000 Leading The Charge

Summary Biohaven Ltd. is a spinout of Biohaven Pharmaceutical, focusing on developing drugs in the life sciences field. BHVN has three Phase 3 drug candidates: troriluzole for OCD, taldefgrobep alfa for SMA, and BHV-7000 for epilepsy and bipolar disorder. Also, the company has a diverse pipeline of drugs in various stages, including those targeting neurology, immunology, and oncology. Upcoming catalysts include FDA approval decisions and clinical trial results, which could significantly impact BHVN's stock performance. Despite the short cash runway, BHVN is a 'buy' due to its promising drug candidates and upcoming catalysts. Read the full article on Seeking Alpha

Analysartikel • Apr 06

We're Keeping An Eye On Biohaven's (NYSE:BHVN) Cash Burn Rate

We can readily understand why investors are attracted to unprofitable companies. By way of example, Biohaven...

Analysartikel • Mar 01

Calculating The Intrinsic Value Of Biohaven Ltd. (NYSE:BHVN)

Key Insights Using the 2 Stage Free Cash Flow to Equity, Biohaven fair value estimate is US$49.64 With US$48.14 share...

Seeking Alpha • Feb 28

Biohaven's Bounce Back: A Missed Call Turns Bullish (Rating Upgrade)

Summary Biohaven's stock rose 130% post "Sell" recommendation; overlooked assets like BHV-7000 suggest early growth stages remain. The company's pipeline, particularly their Kv7 activators and IgG degrader, show promise and have blockbuster potential in treating epilepsy and immune-mediated diseases. Financially, with a cash runway extended to 20.7 months post-offering, Biohaven shows robust short-term health. Upgrading BHVN to "Buy" due to pipeline promise and market potential, despite competition risks and high cash burn. Read the full article on Seeking Alpha

Seeking Alpha • Dec 08

Biohaven Ltd.: Too Far, Too Fast (Rating Downgrade)

Summary Today, we circle back on a promising biopharma concern called Biohaven Ltd., whose shares have had a significant rally in recent months. The company has a diverse pipeline of therapies for neurological and neuropsychiatric diseases, with a mixture of early and late-stage candidates. A portfolio review and analysis around Biohaven follow in the paragraphs below. Read the full article on Seeking Alpha

Analysartikel • Dec 04

Here's Why We're Watching Biohaven's (NYSE:BHVN) Cash Burn Situation

Just because a business does not make any money, does not mean that the stock will go down. For example, Biohaven...

Seeking Alpha • Sep 27

Biohaven: Soaring Share Price On New Data Could Be Too Good To Be True

Summary Biohaven's stock surged nearly 30% following updates on its preclinical asset, the IgA degrader BHV-1300. The company's stock has risen more than 270% since its spinout from parent company Biohaven Pharmaceutical. Biohaven's preclinical pipeline includes assets targeting a wide range of central nervous system conditions and autoimmune diseases. As intriguing as today's data was, it does not necessarily support the buy case for Biohaven. Arguably, the data may have been released in response to promising IgG removal data released by Immunovant earlier this week. Time will tell, but I'm on the sidelines. Read the full article on Seeking Alpha

Seeking Alpha • Aug 28

Biohaven's Valuation Challenge: Weighing Potential Against Setbacks

Summary Biohaven faces FDA rejection for troriluzole; explores further discussions and potential subgroup focus. Despite FDA setback, Biohaven maintains a strong cash position, diversified pipeline, and ongoing R&D efforts. Given current uncertainties and valuation, I recommend a "Sell" stance on Biohaven's stock. Read the full article on Seeking Alpha

Analysartikel • Jul 22

Here's Why We're Watching Biohaven's (NYSE:BHVN) Cash Burn Situation

Just because a business does not make any money, does not mean that the stock will go down. For example, biotech and...

Seeking Alpha • Jun 14

Biohaven: A Promising Investment In Innovative Neurological Therapies

Summary Biohaven offers a diverse portfolio of innovative drug development assets targeting various therapeutic areas, with a focus on neurodegenerative and neuroinflammatory conditions. The company's robust financials, diverse revenue streams, and recent performance results indicate a bright future and strong investment potential. Biohaven's innovative approaches and unique mechanisms of action set it apart from competitors, positioning the company as a compelling investment opportunity in the biopharmaceutical industry. Read the full article on Seeking Alpha

Seeking Alpha • Jun 06

Biohaven: Spinout's Rampant Share Price Gains May Be Giving Pfizer A Headache

Summary Biohaven Ltd is a spinout of assets from Biohaven Pharmaceutical - just before the parent company was acquired by Pfizer last year for >$11bn. Much of the management team that developed Biohaven Pharmaceuticals' Nurtec migraine therapy, plus six other pipeline assets acquired by Pfizer, appear to be working at the new company. Biohaven Ltd shares have risen in value from ~$6, to >$20 - +265% in less than one year. An investor day presentation delivered last week appears to have generated significant upside momentum. An NDA has been submitted to the FDA for approval of a spinocerebellar ataxia Type 3 drug. At a market cap valuation of nearly $1.5bn and with no other near-term approval shots in play, Biohaven shares are not cheap, but the team is experienced. I would not be surprised if the upside momentum continues. Read the full article on Seeking Alpha

Analysartikel • Apr 06

Will Biohaven (NYSE:BHVN) Spend Its Cash Wisely?

We can readily understand why investors are attracted to unprofitable companies. For example, although Amazon.com made...

Seeking Alpha • Feb 21

Biohaven's spinal muscular atrophy therapy gets FDA fast track status

The U.S. Food and Drug Administration (FDA) granted fast track designation to Biohaven (NYSE:BHVN) medicine taldefgrobep alfa to treat spinal muscular atrophy (SMA). SMA is an inherited motor neuron disorder characterized by loss of nerve cells leading to muscle weakness over time. The company noted that taldefgrobep (also known as BHV2000) had previously received received orphan drug designation from the FDA to treat SMA. The drug is currently undergoing a phase 3 trial dubbed RESILIENT. Pfizer had acquired Biohaven Pharmaceuticals but a separate company Biohaven Ltd. was spunoff before the acquisition closed. BHVN +1.82% to $16.81 premarket Feb. 21

Aktieägarnas avkastning

	BHVN	US Biotechs	US Marknad
7D	7.4%	2.3%	0.8%
1Y	16.4%	42.3%	20.2%

Avkastning vs industri: BHVN presterade sämre än US Biotechs branschen som gav 42.3 % under det senaste året.

Avkastning vs Marknaden: BHVN presterade sämre än US marknaden som gav 20.2 % under det senaste året.

Prisvolatilitet

Is BHVN's price volatile compared to industry and market?
BHVN volatility
BHVN Average Weekly Movement	11.7%
Biotechs Industry Average Movement	10.3%
Market Average Movement	7.3%
10% most volatile stocks in US Market	16.7%
10% least volatile stocks in US Market	3.2%

Stabil aktiekurs: BHVN s aktiekurs har varit volatil under de senaste 3 månaderna jämfört med marknaden för US.

Volatilitet över tid: BHVN s veckovolatilitet ( 12% ) har varit stabil under det senaste året, men är fortfarande högre än 75 % av US aktier.

Om företaget

Grundad	Anställda	VD OCH KONCERNCHEF	Webbplats
2022	274	Vlad Coric	www.biohaven.com

Biohaven Ltd. är ett biofarmaceutiskt företag som fokuserar på upptäckt, utveckling och kommersialisering av behandlingar inom immunologi, neurovetenskap och onkologi över hela världen. Företaget utvecklar BHV-1300, som befinner sig i klinisk fas 2 för behandling av Graves sjukdom och reumatoid artrit; BHV-1400, som befinner sig i klinisk fas 2 för behandling av IgA-nefropati; BHV-1600, som befinner sig i klinisk fas 1 för behandling av peripartum kardiomyopati; BHV-8000 som befinner sig i klinisk fas 3-studie för behandling av Parkinsons sjukdom; Opakalim som befinner sig i klinisk fas 3-studie för behandling av fokal epilepsi; BHV-2100 som befinner sig i klinisk fas 2-studie för behandling av smärttillstånd; och BHV-2000 som befinner sig i klinisk fas 2-studie för behandling av fetma. Bolaget utvecklar också BHV-1510, som befinner sig i klinisk fas 2 för behandling av avancerade eller metastaserande epiteliala tumörer, och BHV-1530, som befinner sig i klinisk fas 2 för behandling av urotelial cancer och andra tumörer.

Biohaven Ltd. Sammanfattning av grunderna

Hur förhåller sig Biohaven:s resultat och omsättning till dess börsvärde?
BHVN grundläggande statistik
Börsvärde	US$2.40b
Vinst(TTM)	-US$647.68m
Intäkter(TTM)	n/a

0.0x

P/S-förhållande

-3.7x

P/E-förhållande

Är BHVN övervärderat?

Se Verkligt värde och värderingsanalys

Resultat & intäkter

Viktig lönsamhetsstatistik från den senaste resultatrapporten (TTM)
BHVN resultaträkning (TTM)
Intäkter	US$0
Kostnad för intäkter	US$0
Bruttovinst	US$0
Övriga kostnader	US$647.68m
Intäkter	-US$647.68m

Senast redovisade vinst

Mar 31, 2026

Nästa vinstdatum

n/a

Vinst per aktie (EPS)	-4.30
Bruttomarginal	0.00%
Nettovinstmarginal	0.00%
Skuld/egenkapitalförhållande	186.8%

Hur har BHVN utvecklats på lång sikt?

Se historisk utveckling och jämförelse

Företagsanalys och finansiella data Status

Uppgifter	Senast uppdaterad (UTC-tid)
Analys av företag	2026/07/06 12:21
Aktiekurs vid dagens slut	2026/07/06 00:00
Intäkter	2026/03/31
Årlig intjäning	2025/12/31

Datakällor

Den data som används i vår företagsanalys kommer från S&P Global Market Intelligence LLC. Följande data används i vår analysmodell för att generera denna rapport. Data är normaliserade vilket kan medföra en fördröjning från det att källan är tillgänglig.

Paket	Uppgifter	Tidsram	Exempel US-källa
Företagets finansiella ställning	10 år	Resultaträkning Kassaflödesanalys Balansräkning	SEC Form 10-K SEC Form 10-Q
Analytikernas konsensusuppskattningar	+3 år	Prognos för finansiella poster Analytikernas prismål	Rapporter från analytiker Blue Matrix
Marknadspriser	30 år	Aktiekurser Utdelningar, splittar och åtgärder	ICE Marknadsdata SEC Form S-1
Ägarskap	10 år	Största aktieägare Insiderhandel	SEC Formulär 4 SEC Formulär 13D
Förvaltning	10 år	Ledningsgrupp Styrelse och verkställande direktörer	SEC Form 10-K SEC Form DEF 14A
Viktiga utvecklingstendenser	10 år	Företagsmeddelanden	SEC Formulär 8-K

^* Exempel för amerikanska värdepapper, för icke-amerikanska värdepapper används motsvarande regelverk och källor.

Om inget annat anges är all finansiell data baserad på en årsperiod men uppdateras kvartalsvis. Detta kallas data för efterföljande tolv månader (TTM) eller senaste tolv månader (LTM). Lär dig mer om detta.

Analysmodell och snöflinga

Detaljer om analysmodellen som används för att skapa denna rapport finns på vår Github-sida; vi har också guider om hur du använder våra rapporter och handledningar på Youtube.

Lär dig mer om det team i världsklass som utformade och byggde analysmodellen Simply Wall St.

Industri- och sektormått

Våra bransch- och sektionsmått beräknas var sjätte timme av Simply Wall St, detaljer om vår process finns tillgängliga på Github.

Källor för analytiker

Biohaven Ltd. bevakas av 23 analytiker. 17 av dessa analytiker lämnade de uppskattningar av intäkter eller resultat som användes som indata till vår rapport. Analytikernas inskickade estimat uppdateras löpande under dagen.

Analytiker	Institution
Brian Skorney	Baird
William Pickering	Bernstein
Dina Ramadane	BofA Global Research

Biohaven (BHVN) Aktievy

Belöningar

Riskanalys

Join community and earn perks

Biohaven Ltd. Konkurrenter

Kodiak Sciences

Vericel

Mineralys Therapeutics

Intellia Therapeutics

Prishistorik och prestanda

Senaste nyheter och uppdateringar

Biohaven Advances Opakalim Epilepsy Study and Starts Phase 3 Graves’ Disease Trial

Biohaven Completes Enrollment In RISE3 Pivotal Phase 2/3 Study Evaluating Opakalim In Focal Epilepsy

Biohaven Ltd. Enrolls First Patient in Pivotal Phase 3 Trial of Bhv-1300 for Graves' Disease

Biohaven Begins Pivotal Oncology and Autoimmune Trials as Anticipation Builds

Biohaven (BHVN) Stock Looks Rich After Pivotal Trial Plans Lift Shares

Biohaven: Upgrading To Buy On Protein Degraders Pivotal Study Initiations

Recent updates

Biohaven Advances Opakalim Epilepsy Study and Starts Phase 3 Graves’ Disease Trial

Biohaven Completes Enrollment In RISE3 Pivotal Phase 2/3 Study Evaluating Opakalim In Focal Epilepsy

Biohaven Ltd. Enrolls First Patient in Pivotal Phase 3 Trial of Bhv-1300 for Graves' Disease

Biohaven Begins Pivotal Oncology and Autoimmune Trials as Anticipation Builds

Biohaven (BHVN) Stock Looks Rich After Pivotal Trial Plans Lift Shares

Biohaven: Upgrading To Buy On Protein Degraders Pivotal Study Initiations

Biohaven Begins First Human Trials of Oral BHV-8100 Targeting Metabolic and Immune Disorders

New minor risk - Share price stability

Biohaven Initiates First-In-Human Dosing of Oral Pkm2 Modulator Bhv-8100 Targeting Metabolic Restoration and Immunomodulation

Biohaven Reports Positive Clinical Biomarker and Patient Data for Bhv-1300 and Bhv-1400 in Graves' Disease and Iga Nephropathy

Biohaven Ltd. Reports New Clinical Data In Epilepsy With Opakalim, A Selective Kv7.2/7.3 Activator, Highlighting Seizure Control And Markedly Differentiated Tolerability Profile

Biohaven Ltd. Completes Enrollment In Phase 2 Obesity Study With Taldefgrobep Alfa

Biohaven Ltd., Annual General Meeting, Apr 28, 2026

New major risk - Financial position

Insufficient new directors

Biohaven Highlights Portfolio Progress, Positive Early Patient Data from Priority Degrader Programs

New major risk - Share price stability

Biohaven Ltd. Presents Clinical Safety and Efficacy Data for BHV-1510

Price target decreased by 7.3% to US$39.07

New major risk - Shareholder dilution

Biohaven Ltd. has completed a Follow-on Equity Offering in the amount of $175.000005 million.

New major risk - Negative shareholders equity

Price target decreased by 8.1% to US$42.13

Biohaven Ltd. Announces FDA Issues Complete Response Letter for Biohaven's VYGLXIA (troriluzole) New Drug Application for Spinocerebellar Ataxia

Pomerantz Law Firm Announces the Filing of A Class Action against Biohaven Ltd. and Certain Officers

Consensus revenue estimates decrease by 50%

Price target decreased by 7.7% to US$50.01

Pomerantz Law Firm Announces the Filing of a Class Action Against Biohaven Ltd

Consensus revenue estimates decrease by 22%

Biohaven Ltd. Enrolls First Patient into Phase 2/3 Trial in Early Parkinson's Disease, Targeting Neuroinflammation with Novel Brain-Penetrant TYK2/JAK1 Inhibitor

Biohaven Ltd. Presents Oncology Program Updates and Preliminary Clinical Data Showcasing Innovative Trop2 and Fgfr3 Antibody Drug Conjugates Incorporating Novel Topoix Payload with Potential to Treat A Wide Variety of Tumors

New major risk - Financial position

Consensus revenue estimates fall by 38%

Fda Extends Pdufa Date of Biohaven's Troriluzole Nda for Rare Disease Spinocerebellar Ataxia

An Intrinsic Calculation For Biohaven Ltd. (NYSE:BHVN) Suggests It's 47% Undervalued

Consensus revenue estimates decrease by 14%

Biohaven Ltd. announced that it expects to receive $400 million in funding

New minor risk - Share price stability

Biohaven Ltd. Presents Data Across Innovative Neuroscience Portfolio at the 2025 American Academy of Neurology (AAN) Annual Meeting

Biohaven Ltd., Annual General Meeting, May 05, 2025

Independent Director recently bought US$892k worth of stock

Biohaven Corporation Announces Acceptance and Priority Review by the United States Food and Drug Administration of the New Drug Application for Troriluzole in All-Genotype Spinocerebellar Ataxia

Biohaven's Exciting Year Of Catalysts

Biohaven Ltd. Announces FDA Acceptance and Priority Review of Troriluzole New Drug Application for the Treatment of Spinocerebellar Ataxia

Biohaven: Highly Priced Biotech With Broad Pipeline But No Revenues

Independent Director recently bought US$1.0m worth of stock

Biohaven Ltd. Reports Positive Phase 1 Degrader Data, Achieving Deep Targeted IgG Reductions in the Lowest Subcutaneous Dose Tested

Biohaven's Revenue Path: SCA And Obesity Therapies

Biohaven Ltd. Provides Update on Taldefgrobep Alfa Development Program for Spinal Muscular Atrophy and Obesity

New major risk - Financial position

Biohaven: A Complicated Tale

Biohaven Ltd. has completed a Follow-on Equity Offering in the amount of $250.000005 million.

Biohaven Ltd. Initiates Pivotal Trial of Novel Investigational Drug for Treatment of Migraine

Price target increased by 9.2% to US$62.36

Biohaven: Positive SCA Treatment Data Leads To Q4 2024 NDA Submission Catalyst

Consensus EPS estimates fall by 21%

New major risk - Financial position

Biohaven: Taldefgrobep Alfa Might Have A Place Beyond SMA Treatment

Independent Director recently bought US$1.0m worth of stock

Chief Scientific Officer recently bought US$1.0m worth of stock

Independent Director recently bought US$996k worth of stock

Biohaven Ltd. Showcases Broad Innovative Portfolio and Pipeline Updates Across Multiple Therapeutic Areas Including Immunology, Neuroscience, Metabolic Disorders and Oncology At Annual Investor R&D Day